Comparison of Therapy Selection Drivers Within the S1P Receptor Modulator and Fumarate Classes Among Multiple Sclerosis Patients Who Recently Switched Treatment
Author: Virginia R. Schobel, MSc BACKGROUND: The number of disease-modifying therapies (DMTs) within the S1P receptor modulator and fumarate classes has expanded with recent approvals of siponimod (BAF), ozanimod (RPC), and ponesimod in the S1P class and generic (Gx) dimethyl fumarate (DMF), diroximel fumarate (DRF), and monomethyl fumarate in the fumarate class. OBJECTIVE: To compare […]
Analysis of Health Care Provider Reasons for Switching to Diroximel Fumarate From Other Disease-Modifying Therapies
Authors: Denise Bruen, MSN; Meghan Garabedian, CRNP, MSN, MSCN; Cortnee Roman, MSN, FNP-BC; Nicholas W. Robinson, MA; Meg M. Stabb, MBA; Virginia R. Schobel, MSc; Jason P. Mendoza, Ph.D.; James B. Lewin, PharmD; Mary Zhang, PharmD; Sai L. Shankar, Ph.D. BACKGROUND: Switching of disease-modifying therapies (DMTs) for treatment of multiple sclerosis (MS) is driven by […]
Therapy Selection Considerations During the COVID-19 Pandemic Among Patients With Progressive Multiple Sclerosis: Analyses from Retrospective Patient Chart Audit
Authors: Virginia R. Schobel, MSc; Meg M. Stabb BACKGROUND: In March 2020, the onset of the COVID-19 pandemic in the United States introduced new concerns related to the treatment of multiple sclerosis (MS). OBJECTIVE: To assess the impact of COVID-19-related concerns on disease-modifying therapy (DMT) selection patterns for progressive MS. METHODS: In July-August 2020, US […]
Aduhelm Administration Remains a Trickle, ARIA a Concern
From: Alzforum By: Madolyn Bowman Rogers While three other Alzheimer’s immunotherapies are barreling down the approval pike, the first one to have nabbed a marketing license continues to tread an uncertain path. Several hospital systems have chosen not to provide the drug, and some insurers refuse to cover its cost. Thus far, only a […]
Bristol Myers Squibb’s Zeposia Launch Trajectories Diverge in Germany and the UK Following Negative NICE Decision; Janssen’s Ponvory Could Likewise Stumble
If reimbursement hurdles can be overcome, Zeposia may be well positioned for more favorable early line use and less within-S1P class competition in the UK versus in Germany EXTON, Pa., October 20, 2021 /PRNewswire/ — Following the May 2020 European Medicines Agency (EMA) approval of Bristol Myers Squibb’s Zeposia and the May 2021 approval of Janssen’s Ponvory, […]
Launching a Drug in the Era of COVID-19: How Important is Sales Representative Contact Really?
By: Eric John Pandemic aside (if you can imagine that), launching a drug in the pharmaceutical industry is no walk in the park. There are a number of factors that influence the success (or failure) of a new brand, including clinical performance (efficacy, tolerability, safety, etc.), insurance coverage/cost, and manufacturer perceptions – just to name […]
Amgen’s Aimovig and Eli Lilly’s Emgality Feel the Heat From Strong Uptake of Biohaven’s Nurtec ODT Among Primary Care Physicians for Migraine Prevention, According to Spherix Global Insights
New research suggests that Amgen’s and Eli Lilly’s increased promotional efforts towards PCPs will be vital to minimizing the future impact of Nurtec ODT and AbbVie’s recently approved Qulipta EXTON, Pa., October 12, 2021 /PRNewswire/ — Following the May 2021 FDA approval of Biohaven’s Nurtec ODT for the preventive treatment of episodic migraine, primary care physicians (PCPs) […]
Post-Launch Insights Point to Four Key Factors That Could Drive Future Use of Biogen/Eisai’s Aduhelm in Alzheimer’s Disease
What the Aduhelm manufacturers and others with agents in the pipeline can learn from early launch metrics EXTON, Pa., October 7, 2021 /PRNewswire/ — At three months post-launch, the high expectations for Biogen/Eisai’s Aduhelm in Alzheimer’s disease have not quite materialized. Neurologist-reported patient share for the drug, as well as the percentage of neurologists who have ever […]
AbbVie Pressures Biohaven in Migraine Prevention with FDA Approval for its CGRP Blockbuster-to-be Qulipta
From: FiercePharma By: Angus Liu Tuesday, AbbVie said the FDA has green-lighted its Qulipta, or atogepant, for prevention of episodic migraine. The go-ahead follows the landmark approval of Biohaven’s Nurtec ODT as the first oral anti-CGRP drug for preventing migraine, setting up a direct battle between two meds that both bear big sales expectations. Doctors’ initial […]
Biohaven’s Nurtec ODT Garners Greater Early-Line Use as a Preventive Therapy Among Patients with Less Severe Migraine Compared to Eli Lilly’s Emgality, According to Spherix Patient-Level Data
While efficacy expectations play a key role in the decision to prescribe Nurtec ODT as a preventive therapy, the gepant’s convenient oral dosing profile drives wins over competitors like Emgality EXTON, Pa., September 23, 2021/PRNewswire/ – Just weeks after the FDA approval of Nurtec ODT’s label expansion for the preventive treatment of episodic migraine, Eli […]
